These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
396 related articles for article (PubMed ID: 12468522)
1. A novel DOTA-alpha-melanocyte-stimulating hormone analog for metastatic melanoma diagnosis. Froidevaux S; Calame-Christe M; Tanner H; Sumanovski L; Eberle AN J Nucl Med; 2002 Dec; 43(12):1699-706. PubMed ID: 12468522 [TBL] [Abstract][Full Text] [Related]
2. A gallium-labeled DOTA-alpha-melanocyte- stimulating hormone analog for PET imaging of melanoma metastases. Froidevaux S; Calame-Christe M; Schuhmacher J; Tanner H; Saffrich R; Henze M; Eberle AN J Nucl Med; 2004 Jan; 45(1):116-23. PubMed ID: 14734683 [TBL] [Abstract][Full Text] [Related]
3. DOTA alpha-melanocyte-stimulating hormone analogues for imaging metastatic melanoma lesions. Froidevaux S; Calame-Christe M; Sumanovski L; Tanner H; Eberle AN Ann N Y Acad Sci; 2003 Jun; 994():378-83. PubMed ID: 12851339 [TBL] [Abstract][Full Text] [Related]
4. Radiolabeled alpha-melanocyte-stimulating hormone analogs for receptor-mediated targeting of melanoma: from tritium to indium. Eberle AN; Froidevaux S J Mol Recognit; 2003; 16(5):248-54. PubMed ID: 14523936 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of an (111)In-DOTA-rhenium cyclized alpha-MSH analog: a novel cyclic-peptide analog with improved tumor-targeting properties. Chen J; Cheng Z; Owen NK; Hoffman TJ; Miao Y; Jurisson SS; Quinn TP J Nucl Med; 2001 Dec; 42(12):1847-55. PubMed ID: 11752084 [TBL] [Abstract][Full Text] [Related]
6. Melanoma targeting with DOTA-alpha-melanocyte-stimulating hormone analogs: structural parameters affecting tumor uptake and kidney uptake. Froidevaux S; Calame-Christe M; Tanner H; Eberle AN J Nucl Med; 2005 May; 46(5):887-95. PubMed ID: 15872364 [TBL] [Abstract][Full Text] [Related]
7. Small-animal PET of melanocortin 1 receptor expression using a 18F-labeled alpha-melanocyte-stimulating hormone analog. Cheng Z; Zhang L; Graves E; Xiong Z; Dandekar M; Chen X; Gambhir SS J Nucl Med; 2007 Jun; 48(6):987-94. PubMed ID: 17504880 [TBL] [Abstract][Full Text] [Related]
8. 64Cu-labeled alpha-melanocyte-stimulating hormone analog for microPET imaging of melanocortin 1 receptor expression. Cheng Z; Xiong Z; Subbarayan M; Chen X; Gambhir SS Bioconjug Chem; 2007; 18(3):765-72. PubMed ID: 17348700 [TBL] [Abstract][Full Text] [Related]
9. A (99m)Tc(CO)(3)-labeled pyrazolyl-alpha-melanocyte-stimulating hormone analog conjugate for melanoma targeting. Raposinho PD; Correia JD; Alves S; Botelho MF; Santos AC; Santos I Nucl Med Biol; 2008 Jan; 35(1):91-9. PubMed ID: 18158948 [TBL] [Abstract][Full Text] [Related]
10. Dimeric DOTA-alpha-melanocyte-stimulating hormone analogs: synthesis and in vivo characteristics of radiopeptides with high in vitro activity. Bapst JP; Froidevaux S; Calame M; Tanner H; Eberle AN J Recept Signal Transduct Res; 2007; 27(5-6):383-409. PubMed ID: 18097939 [TBL] [Abstract][Full Text] [Related]
11. Melanoma targeting with alpha-melanocyte stimulating hormone analogs labeled with fac-[99mTc(CO)3]+: effect of cyclization on tumor-seeking properties. Raposinho PD; Xavier C; Correia JD; Falcão S; Gomes P; Santos I J Biol Inorg Chem; 2008 Mar; 13(3):449-59. PubMed ID: 18183429 [TBL] [Abstract][Full Text] [Related]
12. Radioiodination of rhenium cyclized alpha-melanocyte-stimulating hormone resulting in enhanced radioactivity localization and retention in melanoma. Cheng Z; Chen J; Quinn TP; Jurisson SS Cancer Res; 2004 Feb; 64(4):1411-8. PubMed ID: 14973076 [TBL] [Abstract][Full Text] [Related]
13. Glycosylated DOTA-alpha-melanocyte-stimulating hormone analogues for melanoma targeting: influence of the site of glycosylation on in vivo biodistribution. Bapst JP; Calame M; Tanner H; Eberle AN Bioconjug Chem; 2009 May; 20(5):984-93. PubMed ID: 19388674 [TBL] [Abstract][Full Text] [Related]